- Home
- CMA vs CRL Comparison
CMA vs CRL Comparison
Compare CMA & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMA
- CRL
- Stock Information
- Founded
- CMA 1849
- CRL 1947
- Country
- CMA United States
- CRL United States
- Employees
- CMA N/A
- CRL N/A
- Industry
- CMA Major Banks
- CRL Biotechnology: Commercial Physical & Biological Resarch
- Sector
- CMA Finance
- CRL Health Care
- Exchange
- CMA Nasdaq
- CRL Nasdaq
- Market Cap
- CMA 7.7B
- CRL 7.1B
- IPO Year
- CMA N/A
- CRL 2000
- Fundamental
- Price
- CMA $68.00
- CRL $176.91
- Analyst Decision
- CMA Hold
- CRL Buy
- Analyst Count
- CMA 21
- CRL 14
- Target Price
- CMA $62.50
- CRL $184.85
- AVG Volume (30 Days)
- CMA 2.6M
- CRL 807.2K
- Earning Date
- CMA 07-18-2025
- CRL 08-06-2025
- Dividend Yield
- CMA 4.17%
- CRL N/A
- EPS Growth
- CMA 15.05
- CRL N/A
- EPS
- CMA 5.21
- CRL N/A
- Revenue
- CMA $3,215,000,000.00
- CRL $4,022,597,000.00
- Revenue This Year
- CMA $7.26
- CRL N/A
- Revenue Next Year
- CMA $2.83
- CRL $2.49
- P/E Ratio
- CMA $13.06
- CRL N/A
- Revenue Growth
- CMA N/A
- CRL N/A
- 52 Week Low
- CMA $48.12
- CRL $91.86
- 52 Week High
- CMA $73.45
- CRL $254.15
- Technical
- Relative Strength Index (RSI)
- CMA 69.05
- CRL 71.29
- Support Level
- CMA $59.96
- CRL $146.26
- Resistance Level
- CMA $65.94
- CRL $184.17
- Average True Range (ATR)
- CMA 1.76
- CRL 6.31
- MACD
- CMA 0.39
- CRL 1.63
- Stochastic Oscillator
- CMA 98.17
- CRL 80.84
About CMA Comerica Incorporated
With assets of around $80 billion, Comerica is primarily a relationship-based commercial bank headquartered in Dallas. In addition to Texas, Comerica's other primary geographies are California and Michigan, with locations also in Arizona and Florida and select businesses operating in several other states as well as Canada and Mexico.
About CRL Charles River Laboratories International Inc.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.